logo

Chemocentryx Inc. (CCXI)



Trade CCXI now with
  Date
  Headline
4/20/2015 8:12:46 AM ChemoCentryx Begins Clinical Trial Of CCX872 In Pancreatic Cancer
3/12/2015 4:15:09 PM ChemoCentryx Q4 Loss Per Share $0.28 Vs. $0.22 Last Year
12/12/2014 6:32:13 AM ChemoCentryx Reports Positive Results In Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
12/4/2014 8:38:35 AM ChemoCentryx Granted EU Orphan Drug Designation For CCX168
11/17/2014 8:36:36 AM ChemoCentryx Reports Additional Data From Phase II Clinical Trial With CCX168
11/5/2014 5:57:10 PM ChemoCentryx Posts Q3 Loss Per Share Of $0.25 Vs. Loss $0.22 Year Ago
10/20/2014 8:32:38 AM ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
8/5/2014 5:26:24 PM ChemoCentryx Posts Q2 Loss Per Share Of $0.28 Vs. Loss $0.23 Year Ago
6/3/2014 7:04:31 AM ChemoCentryx Says CCX168 Granted Orphan-Drug Designation In ANCA-Associated Diseases By FDA
6/2/2014 5:46:18 AM ChemoCentryx Reports Additional Phase II Data Related To CCX168
5/8/2014 5:25:16 PM ChemoCentryx Posts Q1 Loss Per Share Of $0.27 Vs. Loss $0.28 Year Ago
3/13/2014 4:26:39 PM ChemoCentryx Q4 Loss Per Share Of $0.22 Vs. $0.27 Last Year